Get started
Author

Laura A. Varas

Observed names: Laura Varas, Varas, Laura
ORCID: 0000-0001-8083-0888
Observed ORCID: 0000-0001-8083-0888
OpenAlex ID: A5008420464
Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix
2003 · Lars Bryngelson Ohlsson, Laura Varas, et al. · Experimental and Molecular Pathology · 184
α 10 Integrin Expression Is Up-Regulated on Fibroblast Growth Factor-2-Treated Mesenchymal Stem Cells with Improved Chondrogenic Differentiation Potential
2007 · Laura Varas, Lars Bryngelson Ohlsson, et al. · Stem Cells and Development · 105
Multiple gene copy number enhances insulin precursor secretion in the yeast Pichia pastoris
2005 · Manuel Mansur, Cecilia Cabello, et al. · Biotechnology Letters · 100
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
2022 · Karin Hägerbrand, Laura Varas, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
Modeling of mini-proinsulin production in Pichia pastoris using the AOX promoter
2003 · José M. País, Laura Varas, et al. · Biotechnology Letters · 25
Expression and processing of hepatitis C virus structural proteins in Pichia pastoris yeast
2006 · Gillian Martinez-Donato, Nelson Acosta-Rivero, et al. · Biochemical and Biophysical Research Communications · 23
Recombinant expression of ShPI-1A, a non-specific BPTI-Kunitz-type inhibitor, and its protection effect on proteolytic degradation of recombinant human miniproinsulin expressed in Pichia pastoris
2011 · Dayrom F. Gil, Rossana García-Fernández, et al. · FEMS Yeast Research · 17
PDF
The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2022 · Michelle H. Nelson, Sara Fritzell, et al. · Molecular Cancer Therapeutics · 12
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
2023 · Karin Enell Smith, Sara Fritzell, et al. · Cancer Immunology Immunotherapy · 10
PDF
Expression, purification and characterization of porcine pancreatic Carboxypeptidase B from Pichia pastoris for the conversion of recombinant human insulin
2006 · Manuel Mansur, Liliam Martínez, et al. · Enzyme and Microbial Technology · 7
Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate
2019 · Milaid Granadillo, Aileen Batte, et al. · Vaccine · 6
858 A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies
2020 · Peter Ellmark, Karin Hägerbrand, et al. · Journal for ImmunoTherapy of Cancer · 5
LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs
2017 · Milaid Granadillo, Aileen Batte, et al. · Clinical & Experimental Metastasis · 5
The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response
2015 · Milaid Granadillo, Alain B. Alfonso, et al. · Journal of Cellular Immunotherapy · 5
PDF
Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform
2025 · Barnabas Nyesiga, Karin Hägerbrand, et al. · Drug Delivery · 4
PDF
751 Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb
2021 · Karin Hagerbrand, Mattias Levin, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al. · Cancer Immunology Research · 1
PDF
Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16
2018 · Alain B. Alfonso, Milaid Granadillo, et al. · Journal of Cellular Immunotherapy · 1
PDF
Influence of Cell Disruption Methods on the Recovery and Immunogenicity of a Fusion Protein for a Therapeutic Cancer Vaccine Against HPV
2016 · Miladys Limonta, Laura Varas, et al. · BioProcessing Journal · 1
Data from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S1 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S17 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S15 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Table S2 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S7 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Works count: 52
Citation count: 547
H-index: 9
I10-index: 9
Year
Topic
Type